Corcept Therapeutics (CORT) Shares Outstanding (Diluted Average) (2016 - 2026)

Corcept Therapeutics has disclosed Shares Outstanding (Diluted Average) across 11 years of filings, most recently posting $104.4 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $104.4 million, down 12.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $104.4 million (down 12.84% YoY), and the FY2025 annual result was $120.0 million, up 5.73% from the prior year.
• Shares Outstanding (Diluted Average) came in at $104.4 million for Q1 2026 at Corcept Therapeutics, down from $120.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $120.2 million in Q2 2025 to a low of $104.4 million in Q1 2026.
• The 5-year median for Shares Outstanding (Diluted Average) is $115.0 million (2022), against an average of $114.3 million.
• Across the five-year window, Shares Outstanding (Diluted Average) increased 9.01% in 2025 and decreased 12.84% in 2026, its largest moves.
• Corcept Therapeutics' Shares Outstanding (Diluted Average) stood at $116.0 million in 2022, then declined by 3.64% to $111.7 million in 2023, then advanced by 1.56% to $113.5 million in 2024, then rose by 5.73% to $120.0 million in 2025, then fell by 12.96% to $104.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $104.4 million (Q1 2026), $120.0 million (Q4 2025), and $120.0 million (Q3 2025), per Business Quant data.